Last reviewed · How we verify
ASCs
ASCs are autologous mesenchymal stem cells used to treat various conditions.
ASCs are autologous mesenchymal stem cells used to treat various conditions. Used for Cartilage repair, Orthopedic conditions.
At a glance
| Generic name | ASCs |
|---|---|
| Also known as | Cx401 (company code), Ontaril®, Allogeneic adipose-derived mesenchymal stem cells |
| Sponsor | Tigenix S.A.U. |
| Drug class | Stem cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative medicine |
| Phase | Phase 2 |
Mechanism of action
ASCs are derived from a patient's own fat tissue and have the ability to differentiate into various cell types, promoting tissue repair and regeneration.
Approved indications
- Cartilage repair
- Orthopedic conditions
Common side effects
- Pain
- Swelling
- Infection
Key clinical trials
- Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments (PHASE2)
- Skin Color Matching in Head and Neck Reconstructive Surgery (NA)
- ASCs in Recently Diagnosed Non-ischemic Heart Failure (PHASE2)
- Adipose-Derived Stromal Cells (ASC's) for Pressure Ulcers (PHASE1)
- Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis (PHASE1)
- Effect of Mesenchymal Stem Cells on Healing of Foot Ulcers in Diabetes Patients. (PHASE1)
- Evaluation of the Safety and Efficacy of Live ASCs in the Treatment of Diabetic Foot (FOOTCELL) (PHASE2)
- Borrelia B-cell Diagnostics
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASCs CI brief — competitive landscape report
- ASCs updates RSS · CI watch RSS
- Tigenix S.A.U. portfolio CI